Here’s whether Nuvation Bio Inc. (NUVB) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.08% over 10 days); RSI 62 — healthy momentum range; strong 1-year return of +94.3%. Concerns: trading below the 200-day MA (long-term downtrend). Currently 50.6% off its 52-week high. Score: +2/7.
NUVB is trading below its 200-day MA ($5.23) — a key warning sign the longer-term trend is under pressure. An RSI of 61.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +94.3% compares to +24.4% for SPY (beat the market by 70.0%). The current 50.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $19,435 today
vs. S&P 500 (SPY) — same period beat market by 70.0%